Sterile Basics: How to Know if Your Cleanroom Can Consistently Operate Within a State of Control

Area of Science:

• Pharmaceutical Compounding
• Microbiology
• Environmental Monitoring

Background:

• Sterile compounding relies on engineering controls to maintain product sterility.
• The United States Pharmacopeia (USP) Chapter <797> has been revised, increasing testing frequency for microbiological contaminants.
• Facilities not purpose-built or not in a state of control may exceed USP action levels.

Purpose of the Study:

• To assess the impact of dynamic operations on bioburden in sterile compounding areas.
• To establish a baseline for cleanroom performance before the USP <797> revision becomes enforceable.
• To provide statistically significant data on environmental microbiological contamination levels.

Main Methods:

• Conducting an environmental-baseline study in sterile compounding facilities.
• Sampling and testing classified areas for microbiological contaminants.
• Assessing the influence of dynamic operations on bioburden levels.

Main Results:

• Facilities may struggle to meet new, more frequent USP <797> testing requirements.
• Non-purpose-built or poorly controlled facilities are predicted to exceed action levels.
• Baseline data is crucial for understanding cleanroom performance under operational stress.

Conclusions:

• Proactive environmental-baseline studies are essential for sterile compounding sites.
• Understanding bioburden dynamics is critical for compliance with revised USP <797> standards.
• Facilities must prepare for increased scrutiny of environmental controls and microbial monitoring.